Clinical Trials
5 trialsNCT04463953 2026-02-11
Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Completed
NCT04116437 2026-01-28
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
BeOne Medicines
Phase 2 Completed
NCT04172246 2025-11-21
Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies
BeOne Medicines
Phase 1/2 Completed
NCT03053440 2024-10-26
ASPEN
BeiGene
Phase 3 Completed
NCT03332173 2024-10-26
Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)
BeiGene
Phase 2 Completed